九洲药业公告称，近日收到国家药监局颁发的关于甲苯磺酸艾多沙班的《化学原料药上市申请批准通知 书》。该药品为口服抗凝药，公司于2024年7月提交上市申请。截至目前，公司在该原料药累计研发投 入约669万元。2023年，甲苯磺酸艾多沙班片在国内样本医院和城市实体药店销售额约3.61亿元。此次 获批将丰富公司产品结构，提升竞争力，但短期内对业绩无重大影响，且药品产销有不确定性。 ...

证券代码：603456 证券简称：九洲药业 公告编号：2025-068 浙江九洲药业股份有限公司 关于公司收到化学原料药上市申请批准通知书 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，浙江九洲药业股份有限公司（以下简称"公司"）收到国家药品监督 管理局（以下简称"国家药监局"）颁发的关于甲苯磺酸艾多沙班的《化学原料 药上市申请批准通知书》（通知书编号：2025YS01026），具体情况如下： 一、药品的基本情况 药品名称：甲苯磺酸艾多沙班 注册标准编号：YBY71722025 包装规格：1kg/桶，2kg/桶，5kg/桶，10kg/桶，15kg/桶，20kg/桶，25kg/桶 申请事项：境内生产化学原料药上市申请 生产企业：浙江九洲药业股份有限公司，浙江省台州市椒江区外沙路工业区 （外沙路 99 号） 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册。质量标准、标签及生产工艺照所附执行。 二、药品其他相关情况 甲苯磺酸艾多沙班是一种口服抗凝药物，主要用于预防 ...

Core Viewpoint - Jiuzhou Pharmaceutical has received approval from the National Medical Products Administration for the marketing application of tolvaptan sulfate, an oral anticoagulant drug [1] Group 1: Company Information - Jiuzhou Pharmaceutical (603456) announced the receipt of a marketing approval notification for tolvaptan sulfate on November 24 [1] - Tolvaptan sulfate is primarily used for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment or prevention of deep vein thrombosis and pulmonary embolism [1]

九洲药业（603456）(603456.SH)公告，公司收到国家药品监督管理局颁发的关于甲苯磺酸艾多沙班的 《化学原料药上市申请批准通知书》。甲苯磺酸艾多沙班是一种口服抗凝药物，主要用于预防非瓣膜性 房颤患者的卒中及全身性栓塞，以及治疗或预防深静脉血栓和肺栓塞。 ...

智通财经APP讯，九洲药业(603456.SH)公告，公司收到国家药品监督管理局颁发的关于甲苯磺酸艾多 沙班的《化学原料药上市申请批准通知书》。甲苯磺酸艾多沙班是一种口服抗凝药物，主要用于预防非 瓣膜性房颤患者的卒中及全身性栓塞，以及治疗或预防深静脉血栓和肺栓塞。 ...

（文章来源：证券日报） 证券日报网讯九洲药业11月21日在互动平台回答投资者提问时表示，股价表现受宏观环境、行业政策、 市场行情及板块轮动等多重因素综合影响，为稳定市场预期、传递长期发展信心，公司已扎实推进系列 市值管理举措：2025年股份回购计划实施完毕，2024年回购库存股完成注销，同时顺利实施2025年半年 度分红方案。未来公司将以稳健经营为基础，积极向资本市场传递核心价值，切实为创造长期、稳定的 投资回报。 ...

Market Overview - The medical services sector experienced a decline of 2.71% on November 21, with Baihua Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3834.89, down 2.45%, while the Shenzhen Component Index closed at 12538.07, down 3.41% [1] Stock Performance - Notable gainers included Yangguang Nuohua, which rose by 4.47% to a closing price of 61.21, with a trading volume of 86,300 shares and a transaction value of 530 million [1] - Baihua Pharmaceutical saw a significant decline of 9.67%, closing at 9.06, with a trading volume of 292,400 shares and a transaction value of 275 million [2] - Other notable decliners included Chengda Pharmaceutical (-9.58%), Berry Genomics (-8.67%), and Guangzheng Eye Hospital (-7.26%) [2] Capital Flow - The medical services sector experienced a net outflow of 1.325 billion in institutional funds, while retail investors saw a net inflow of 1.332 billion [2] - The table of capital flow indicates that major stocks like Yangguang Nuohua had a net inflow of 10.986 million from institutional investors, while retail investors had a net inflow of 1.374 million [3]

11月20日，九洲药业跌2.09%，成交额4.87亿元。两融数据显示，当日九洲药业获融资买入额6575.20万 元，融资偿还5960.66万元，融资净买入614.55万元。截至11月20日，九洲药业融资融券余额合计6.20亿 元。 资料显示，浙江九洲药业股份有限公司位于浙江省台州市椒江区外沙路99号，成立日期1998年7月13 日，上市日期2014年10月10日，公司主营业务涉及化学原料药及医药中间体的研发、生产与销售。主营 业务收入构成为：新药定制研发和生产服务(CDMO)79.81%，特色原料药及中间体18.22%，其他 1.96%。 截至9月30日，九洲药业股东户数5.92万，较上期增加10.22%；人均流通股15035股，较上期减少 9.27%。2025年1月-9月，九洲药业实现营业收入41.60亿元，同比增长4.92%；归母净利润7.48亿元，同 比增长18.51%。 分红方面，九洲药业A股上市后累计派现21.83亿元。近三年，累计派现12.45亿元。 机构持仓方面，截止2025年9月30日，九洲药业十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股2036.80万股，相比上期增加781 ...

Investment Rating - The report suggests focusing on globally competitive CXO companies such as WuXi AppTec, WuXi XDC Cayman, WuXi Biologics Cayman, Pharmaron, Asymchem Laboratories, Porton Pharma Solutions, and Zhejiang Jiuzhou Pharmaceutical [29][30] Core Insights - The overseas CXO industry has confirmed a bottom in prosperity and is showing signs of structural recovery. The industry has passed the cyclical bottom, but recovery is characterized by significant structural differentiation [30] - Clinical CROs like IQVIA and Medpace are leading the recovery with strong orders and guidance, while CDMOs such as Lonza demonstrate resilience through long-term contracts. Preclinical CROs and research services are still stabilizing, with improving inquiry or order cancellation rates [30][31] - The overall recovery strength and sustainability will depend on the continuation of enthusiasm in biotech financing [30] Summary by Sections 1. Overseas CXO Industry Q3 2025 Performance Review - The overseas CXO industry has shown a structural recovery trend, with significant differentiation in recovery across sectors. Clinical CROs are leading the recovery, while preclinical CROs and research services are still in a stabilization phase [8][30] 2. Leading Company Analysis 2.1 Charles River - The company is nearing a performance bottom, with Q3 revenue at $1 billion and an organic growth rate of -1.6%. The management has raised the full-year revenue and EPS guidance, indicating a positive outlook for 2026 [15][16] 2.2 Samsung Biologics - The company reported a strong Q3 performance with revenue of 1.66 trillion KRW, a 40% YoY increase. The CDMO segment continues to grow, with a full-year revenue growth guidance of 25%-30% [19][20] 2.3 Lonza - Lonza's Q3 performance met expectations, with CDMO business projected to grow by 20%-21% YoY. The company is experiencing strong demand in its core business segments [24][25] 3. Key Financial Metrics - The report includes financial forecasts for various companies, indicating expected revenue growth and profitability metrics for 2025-2027. For instance, WuXi AppTec is expected to have an EPS of 5.42 in 2025, with a PE ratio of 18 [26]

Market Overview - The medical services sector experienced a decline of 1.09% on November 19, with Jiuzhou Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3946.74, up 0.18%, while the Shenzhen Component Index closed at 13080.09, unchanged [1] Individual Stock Performance - Jiuzhou Pharmaceutical (603456) saw a significant drop of 6.24%, closing at 20.12, with a trading volume of 446,900 shares and a turnover of 915 million [2] - Other notable declines included Zhaoyan New Drug (603127) down 5.08% and ST Zhongzhu (600568) down 5.04% [2] - In contrast, some stocks like WuXi AppTec (603259) and Haoyuan Pharmaceutical (688131) showed slight increases of 0.95% and 0.34%, respectively [1] Capital Flow Analysis - The medical services sector experienced a net outflow of 885 million from institutional investors, while retail investors saw a net inflow of 877 million [2][3] - The data indicates that institutional investors are pulling back, while retail investors are actively buying into the sector [3] Stock-Specific Capital Flow - WuXi AppTec (603259) had a net inflow of 66.82 million from institutional investors, while it faced a net outflow of 15.56 million from retail investors [3] - Other stocks like Yinuo Pharmaceutical (688710) and Sunshine Nuohua (688621) also showed mixed capital flows, with varying degrees of institutional and retail investor activity [3]